The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty

Dmitriy Alekseevich Sychev, Alexander Nikolaevich Levanov, Tatiana Vladimirovna Shelekhova, Pavel Olegovich Bochkov, Natalia Pavlovna Denisenko, Kristina Anatolyevna Ryzhikova, Karin Badavievich Mirzaev, Elena Anatolyevna Grishina, Mikhail Alekseevich Gavrilov, Galina Vladislavovna Ramenskaya, Aleksei Vladimirovich Kozlov, Tanya Bogoslovsky, Dmitriy Alekseevich Sychev, Alexander Nikolaevich Levanov, Tatiana Vladimirovna Shelekhova, Pavel Olegovich Bochkov, Natalia Pavlovna Denisenko, Kristina Anatolyevna Ryzhikova, Karin Badavievich Mirzaev, Elena Anatolyevna Grishina, Mikhail Alekseevich Gavrilov, Galina Vladislavovna Ramenskaya, Aleksei Vladimirovich Kozlov, Tanya Bogoslovsky

Abstract

Background: Non-vitamin K oral anticoagulants (NOACs) are commonly used for prophylaxis of venous thromboembolism (VTE) in orthopedic patients. Despite known safety and high potency of NOACs, potential interactions of NOACs with genetic polymorphisms are poorly understood. Dabigatran etexilate is one of the most commonly prescribed direct thrombin inhibitors for the prevention of VTE. The objectives of this study were to assess the effect of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) polymorphisms on dabigatran pharmacokinetics in patients after total knee arthroplasty.

Patients and methods: A total of 60 patients, aged 37-81 years, who underwent surgery for knee replacement have been included in the study. VTE prophylaxis was conducted via administration of dabigatran etexilate 220 mg once daily. Genotyping for carrier state of polymorphic variants such as rs1045642 and rs4148738 of the ABCB1 gene and rs2244613 of the CES1 gene was carried out using real-time polymerase chain reaction (PCR). We also measured the peak and trough concentrations of plasma dabigatran by using high-performance liquid chromatography (HPLC).

Results: Our study revealed that TT genotype of rs1045642 polymorphism of the ABCB1 gene was associated with higher dabigatran equilibrium peak concentrations and the higher risk of bleeding than the presence of CC genotype (p<0.008). There was no statistically significant genotype-dependent difference in the trough concentrations between rs1045642 and rs4148738 of the ABCB1 gene and rs2244613 of the CES1 gene.

Conclusion: Our findings indicate that the polymorphisms of ABCB1 rs1045642 may have a prominent contribution to the safety of dabigatran in patients after knee surgery. Moreover, TT genotype may be associated with the higher risk of hemorrhagic complications in this population. There were no influence of polymorphism of ABCB1 rs4148738 and CES1 rs2244613 on dabigatran peak and through concentrations. Larger studies are needed to confirm our observations.

Keywords: ABCB1; CES1; dabigatran; new oral anticoagulants; pharmacogenetics; venous thromboembolism.

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Peak plasma concentrations of dabigatran in patients after knee surgery with respect to the genotype ABCB1 rs4148738. Abbreviations: Max, maximum; Min, minimum.
Figure 2
Figure 2
Peak plasma concentrations of dabigatran in patients after knee surgery with respect to genotype ABCB1 rs1045642. Abbreviations: Max, maximum; Min, minimum.
Figure 3
Figure 3
Peak plasma concentrations of dabigatran in patients after knee surgery with respect to genotype CES1 rs2244613. Abbreviations: Max, maximum; Min, minimum.
Figure 4
Figure 4
Peak plasma concentrations of dabigatran with respect to haplotype combinations of polymorphisms of ABCB1 (rs1045642 CT+TT)/CES1 (rs2244613 CC) compared to the subset of the remaining haplotype combinations. Abbreviations: Max, maximum; Min, minimum.
Figure 5
Figure 5
Trough plasma concentrations of dabigatran with respect to genotype ABCB1: (A) rs1045642; (B) rs4148738; (C) CES1 rs2244613. Abbreviations: Max, maximum; Min, minimum.

References

    1. Borisov DB, Kirov MY. Endoprosthesis replacement of hip and knee joints: epidemiological aspects and effect on quality of life. Hum Ecol. 2013;(8):52–57.
    1. Shevchenko YL, Stoyko YM, Zamyatin MN, et al. Multimodal prevention of venous thromboembolic complications after total hip and knee joint endoprosthesis. Meditsinskiy Sov. 2014;2:8–12.
    1. Diacov I. New oral anticoagulants – a place in the domestic pharmaceutical market. Remedium Period Pharm Med Equip Mark. 2014;(11):42–43.
    1. Kouzmin II, Akhtiamov IF, Sorokin VA. Thromboembolic complications in the hip endoprosthetics. Orthop Genius. 2004;(4):63–68.
    1. Bokeria LA, Zatevachin II, Kirienko AI, et al. Russian clinical guidelines for the diagnosis, treatment and prevention of venous thromboembolic complications (VTEC) Flebologia. 2015;4(2):1–52.
    1. Zhirova TA, Zubkov EA, Reino EV, Bogatkin AA, Kuznetsova OA, Mashinskaya TM. Venous thromboses prevention in orthopedics. Recommendations and real practice. 2012;3:142–144.
    1. Bozhkova SA. Specificity of anticoagulant choice for VTE prophylaxes after major orthopedic surgery – the view of clinical pharmacologists. Traumatol Orthop Russ. 2011;1(59):1–6.
    1. Instructions on Medical Use of a Medicinal Product PRADAXA. 2016. [Accessed May 31, 2018]. Available from: .
    1. Kurdyukov ID, Shmurak VI, Nadeyev AD, Voitenko NG, Prokofyeva DS, Goncharov NV. «Esterase status» of the organism at exposure to toxic substances and pharmaceutical preparations. Toxicol Rev. 2012;(6):6–12.
    1. Lockridge O, Quinn DM. 414 – Esterases. In: McQueen CA, editor. Comprehensive Toxicology (Second Edition) Kidlington, UK: Elsevier Ltd; 2010. pp. 243–273.
    1. Sychev DA, Kryukov AV, Tereshchenko OV. Pharmacogenetic aspects of new oral anticoagulants application. Ration Pharmacother Cardiol. 2017;13(3):416–421.
    1. Paré G, Eriksson N, Lehr T, et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013;127(13):1404–1412.
    1. Liesenfeld KH, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9(11):2168–2175.
    1. Gilyarov MY. Dabigatran: how to select an optimal dose in clinical practice? J Arrhythmol. 2012;(69):77–80.
    1. Shi J, Wang X, Nguyen JH, et al. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Biochem Pharmacol. 2016;119:76–84.
    1. Zhu HJ, Appel DI, Johnson JA, Chavin KD, Markowitz JS. Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril. Biochem Pharmacol. 2009;77(7):1266–1272.
    1. Zhu HJ, Markowitz JS. Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants. Drug Metab Dispos. 2009;37(2):264–267.
    1. Dimatteo C, D’Andrea G, Vecchione G, et al. Pharmacogenetics of dabigatran etexilate interindividual variability. Thromb Res. 2016;144:1–5.
    1. Biophen® Dabigatran Calibrator Low. 2014. [Accessed May 31, 2018]. Available from: .
    1. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Guidance for Industry Establishing Bioequivalence Guidance for Industry Statistical Approaches to. Vol. 4. Rockville, MD: 2001.
    1. Vasilenko GF, Davydova KS, Krasnykh LM, Savchenko YA, Shohin IE. Methodological Recommendations for Drug Manufacturers on in Vitro Equivalence Test for Generic Drug Products according to Biowaiver Procedure (DRAFT) Moscow: Federal Service on Surveillance in Healthcare and Social Development; 2010.
    1. European Medicines Agency . In: Guideline on the Investigation of Bioequivalence. EMEA, editor. London: 2018.
    1. Zhu H, Appel DI, Jiang Y, Markowitz JS. Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver. Drug Metab Dispos. 2009;37(9):1819–1825.
    1. Shulkin AV, Yakusheva EN, Popova NM. The role of P-glycoprotein in rational pharmacotherapy in cardiology. Ration Pharmacother Cardiol. 2013;9(6):701–707.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj